Literature DB >> 23053508

Two cases of partial dominant interferon-γ receptor 1 deficiency that presented with different clinical courses of bacille Calmette-Guérin multiple osteomyelitis.

Kaoru Obinata1, Tsubasa Lee, Takahiro Niizuma, Keiji Kinoshita, Toshiaki Shimizu, Takayuki Hoshina, Yuka Sasaki, Toshiro Hara.   

Abstract

We experienced two cases of unrelated Japanese children with bacille Calmette-Guérin (BCG) multiple osteomyelitis with partial interferon (IFN)-γ receptor 1 (IFNGR1) deficiency. Heterozygous small deletions with frame shift (811 del4 and 818 del4) were detected, which were consistent with the diagnosis of partial dominant IFNGR1 deficiency. Case 1: a 2-year-old boy visited us because of limb and neck pain. He had been vaccinated with BCG at 17 months of age. Multiple destructive lesions were observed in the skull, ribs, femur, and vertebral bones. Mycobacterium bovis (BCG Tokyo 172 strain by RFLP technique) was detected in the bone specimen. The BCG multiple osteomyelitis was treated successfully without recurrence. Case 2: an 18-month-old girl developed multiple osteomyelitis 9 months after BCG inoculation. Radiologic images showed multiple osteolytic lesions in the skull, ribs, femur, and vertebrae. M. bovis (BCG Tokyo 172 strain) was detected in the cultures from a bone biopsy. Her clinical course showed recurrent osteomyelitis and lymphadenitis with no pulmonary involvement. The effects of high-dose antimycobacterial drugs and IFN-γ administration were transient, and complete remission has since been achieved by combination antimycobacterial therapy, including levofloxacin. Partial dominant IFNGR1 deficiency is a rare disorder, but it should be considered when a patient presents with multiple osteomyelitis after BCG vaccination. The cases that are resistant to conventional regimens require additional second-line antituberculous drugs, such as levofloxacin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23053508     DOI: 10.1007/s10156-012-0493-5

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  5 in total

Review 1.  Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-γ immunity.

Authors:  Jacinta Bustamante; Stéphanie Boisson-Dupuis; Laurent Abel; Jean-Laurent Casanova
Journal:  Semin Immunol       Date:  2014-10-26       Impact factor: 11.130

Review 2.  Intact IFN-γR1 expression and function distinguishes Langerhans cell histiocytosis from mendelian susceptibility to mycobacterial disease.

Authors:  Willemijn T Quispel; Janine A Stegehuis-Kamp; Susy J Santos; Annelies van Wengen; Edward Dompeling; R Maarten Egeler; Esther van de Vosse; Astrid G S van Halteren
Journal:  J Clin Immunol       Date:  2013-11-20       Impact factor: 8.317

Review 3.  Laboratory evaluation of the IFN-γ circuit for the molecular diagnosis of Mendelian susceptibility to mycobacterial disease.

Authors:  Ana Esteve-Solé; Ithaisa Sologuren; María Teresa Martínez-Saavedra; Àngela Deyà-Martínez; Carmen Oleaga-Quintas; Rubén Martinez-Barricarte; Andrea Martin-Nalda; Manel Juan; Jean-Laurent Casanova; Carlos Rodriguez-Gallego; Laia Alsina; Jacinta Bustamante
Journal:  Crit Rev Clin Lab Sci       Date:  2018-03-04       Impact factor: 6.250

4.  Multifocal Recurrent Osteomyelitis and Hemophagocytic Lymphohistiocytosis in a Boy with Partial Dominant IFN-γR1 Deficiency: Case Report and Review of the Literature.

Authors:  Aidé Tamara Staines-Boone; Caroline Deswarte; Edna Venegas Montoya; Luz María Sánchez-Sánchez; Jorge Alberto García Campos; Teodoro Muñiz-Ronquillo; Jacinta Bustamante; Francisco J Espinosa-Rosales; Saul Oswaldo Lugo Reyes
Journal:  Front Pediatr       Date:  2017-05-03       Impact factor: 3.418

5.  Promoting effect of long non-coding RNA SNHG1 on osteogenic differentiation of fibroblastic cells from the posterior longitudinal ligament by the microRNA-320b/IFNGR1 network.

Authors:  Yuqiang Wang; Huixia Niu; Yilin Liu; Hao Yang; Min Zhang; Limin Wang
Journal:  Cell Cycle       Date:  2020-10-05       Impact factor: 4.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.